Last 1,369 INR
Change Today -0.30 / -0.02%
Volume 7.0K
NTCPH On Other Exchanges
Symbol
Exchange
Natl India
As of 11:47 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

natco pharma ltd (NTCPH) Snapshot

Open
1,365
Previous Close
1,369
Day High
1,376
Day Low
1,352
52 Week High
09/16/14 - 1,590
52 Week Low
04/1/14 - 650.00
Market Cap
45.5B
Average Volume 10 Days
129.4K
EPS TTM
32.16
Shares Outstanding
33.2M
EX-Date
02/24/14
P/E TM
42.6x
Dividend
5.00
Dividend Yield
0.37%
Current Stock Chart for NATCO PHARMA LTD (NTCPH)

Related News

No related news articles were found.

natco pharma ltd (NTCPH) Related Businessweek News

No Related Businessweek News Found

natco pharma ltd (NTCPH) Details

NATCO Pharma Limited operates as a pharmaceutical company in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic segments, such as anti-neoplastics, anti-depressants, anti-migraine, anti- osteoporosis, anti-asthma, proton pump inhibitors, and therapeutic peptides. It also provides generic oncology products for the treatment of hematology and solid tumors under the brand names of Geftinat, Erlonat, Veenat, and Sorafenat. In addition, it provides formulations, such as Ondansetron, Anastrozole, Letrozole, Trihexyphenidyl, Cholorquine Phosphate, and Citalopram, as well as is engaged in the retail pharmacy business and contract manufacturing activities. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

Founded in 1981

natco pharma ltd (NTCPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

natco pharma ltd (NTCPH) Key Developments

Natco Pharma Limited Announces Management Appointments

Natco Pharma Limited announced that the Board of Directors of the company at its meeting held on November 12, 2014, Mr. P S R K Prasad, Executive Vice President (Corporate Engineering Services) appointed as Additional Director of the company who will be in the whole time employment of the company. Mr. S V V N Appa Rao, Vice President (Finance & Accounts) appointed as Interim (Chief Financial Officer) of the company.

Natco Pharma Ltd. Announces Unaudited Consolidated and Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Natco Pharma Ltd. announced unaudited consolidated and standalone earnings results for the second quarter and six months ended September 30, 2014. For the second quarter, on standalone basis, the company reported net sales/income from operations of INR 1,811.1 million against INR 1,337.5 million a year ago. Total income from operations was INR 1,912.8 million against INR 1,500.6 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 506.5 million against INR 400.7 million a year ago. Profit from ordinary activities before tax was INR 466.6 million against INR 322.7 million a year ago. Net profit for the period was INR 348 million or INR 10.52 per basic and diluted share before and after extraordinary items against INR 286.9 million or INR 9.15 per diluted share before and after extraordinary items a year ago. For the six months, on standalone basis, the company reported net sales/income from operations of INR 3,431.1 million against INR 2,706.0 million a year ago. Total income from operations was INR 3,727.6 million against INR 2,948.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,010.2 million against INR 787.5 million a year ago. Profit from ordinary activities before tax was INR 915.5 million against INR 648.7 million a year ago. Net profit for the period was INR 712.1 million or INR 21.53 per basic and diluted share before and after extraordinary items against INR 514.3 million or INR 16.40 per diluted share before and after extraordinary items a year ago. For the second quarter, on consolidated basis, the company reported net sales/income from operations of INR 2,090.6 million against INR 1,629.1 million a year ago. Total income from operations was INR 2,192.3 million against INR 1,792.2 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 477 million against INR 360.1 million a year ago. Profit from ordinary activities before tax was INR 436.5 million against INR 279.7 million a year ago. Net profit from ordinary activities after tax was INR 323.7 million or INR 9.79 per basic and diluted share before and after extraordinary items against INR 269.2 million or INR 8.58 per diluted share before and after extraordinary items a year ago. For the six months, on consolidated basis, the company reported net sales/income from operations of INR 3,993.6 million against INR 3,274.5 million a year ago. Total income from operations was INR 4,290.1 million against INR 3,517.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 940.7 million against INR 733.8 million a year ago. Profit from ordinary activities before tax was INR 846.4 million against INR 588.8 million a year ago. Net profit from ordinary activities after tax was INR 658.3 million or INR 19.91 per basic and diluted share before and after extraordinary items against INR 487.0 million or INR 15.52 per diluted share before and after extraordinary items a year ago.

Natco Pharma Limited, Board Meeting, Nov 12, 2014

Natco Pharma Limited, Board Meeting, Nov 12, 2014. Agenda: To consider the unaudited financial results for the quarter ended September 30, 2014 and related matters; to consider executive appointments; and to consider other issues.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTCPH:IN 1,368.50 INR -0.30

NTCPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Momenta Pharmaceuticals Inc $10.82 USD -0.04
Mylan Inc/PA $56.30 USD -0.50
Teva Pharmaceutical Industries Ltd $59.06 USD +0.06
View Industry Companies
 

Industry Analysis

NTCPH

Industry Average

Valuation NTCPH Industry Range
Price/Earnings 37.8x
Price/Sales 5.6x
Price/Book 5.8x
Price/Cash Flow 29.1x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATCO PHARMA LTD, please visit www.natcopharma.co.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.